文献速递静脉血栓栓塞

AngioJet流变血栓清除术治疗急性双侧髂股深静脉血栓的疗效、安全性与短期结果初步经验

A preliminary experience on the efficacy, safety, and short-term results in the treatment of acute bilateral iliofemoral deep vein thrombosis with the Angiojet rheolytic thrombectomy.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-01-19

本研究评估AngioJet流变血栓清除术治疗急性双侧髂股深静脉血栓的早期临床结局,重点关注血栓后综合征发生率。2021年3月至2023年8月连续纳入16例患者,技术成功、完全清除血栓和症状缓解均达100%,6个月和12个月一期通畅率分别为92%和91%,但3例(19%)术后死亡,1例(6%)发生大面积肺栓塞。

要点

  • 16例急性双侧髂股深静脉血栓患者接受AngioJet流变血栓清除术,技术成功和症状缓解均达100%。
  • 术后6个月和12个月一期通畅率分别为92%和91%,随访期间1例再闭塞。
  • 3例(19%)术后死亡,1例(6%)发生大面积肺栓塞,作者认为老年患者可行性是显著问题。

核心结论

  • AngioJet流变血栓清除术治疗双侧髂股深静脉血栓提供有前景的结果,在高成功率和严重症状患者早期症状改善方面表现良好。
  • 在这一早期病例系列中,AngioJet装置在老年病例中的可行性似乎是一个显著问题,因此患者选择至关重要。

研究设计与样本

  • 2021年3月至2023年8月在本中心连续纳入16例接受AngioJet流变血栓清除术治疗的急性双侧髂股深静脉血栓患者。
  • 主要结局包括目标静脉通畅、血栓后综合征发生、复发性深静脉血栓和手术相关死亡。
  • 次要结局包括轻微或大出血、急性肾损伤、记录到的血红蛋白尿、心脏事件、肺栓塞、肢体丢失和死亡。

主要发现

  • 患者平均年龄69±12岁(范围53-87岁),恶性肿瘤和近期大手术是最常见危险因素,各占25%(n=4)。
  • 所有患者(n=16,100%)实现技术成功、完全血栓清除和症状缓解。
  • 4例(25%)术后出现短暂血红蛋白尿,经充分补液后自行缓解;3例(19%)发生轻微出血,无大出血并发症。
  • 1例(6%)术后发生急性肾损伤和短暂心动过缓;3例(19%)术后死亡;1例(6%)发生术后大面积肺栓塞。
  • 平均随访11±6个月(范围5-19个月),术后6个月和12个月一期通畅率分别为92%和91%,随访期间1例发生再闭塞。

临床怎么用

  • 作者认为AngioJet流变血栓清除术治疗双侧髂股深静脉血栓提供有前景的结果,但老年病例中装置可行性似乎是显著问题,患者选择至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to examine the early clinical outcomes of AngioJet rheolytic thrombectomy (RT) in patients with acute bilateral iliofemoral deep vein thrombosis (IFDVT), with a specific focus on the incidence of post-thrombotic syndrome. METHODS: From March 2021 to August 2023, 16 consecutive patients with acute bilateral IFDVT treated with AngioJet RT at our center were evaluated. Primary outcomes include patency of the target veins, development of post-thrombotic syndrome, recurrent DVT, and procedure-related death. Secondary outcomes included minor or major bleeding, acute kidney injury, documented hemoglobinuria, cardiac event, pulmonary embolism, limb loss, and death. RESULTS: The mean age of the patients was 69 ± 12 years (range, 53-87 years). Malignancy and recent major surgery were the most prevalent risk factors, each observed in 25% of patients (n = 4). Technical success, complete clot removal, and alleviation of symptoms were achieved in all patients (n = 16; 100%). In one-quarter of the patients (n = 4), transient hemoglobinuria was observed following the procedure. This complication resolved spontaneously after adequate fluid replenishment. Minor bleeding occurred in three patients (19%), whereas no patients had major bleeding complication. There was one postoperative acute kidney injury and transient bradycardia (6%). Three patients died after the procedures (19%). One patient (6%) developed postoperative massive pulmonary embolism. The mean follow-up was 11 ± 6 months (range, 5-19 months). The primary patency rate was 92% and 91%, respectively, 6 and 12 months after procedures. One patient had reocclusion during the follow-up. CONCLUSIONS: AngioJet RT applied to patients with bilateral IFDVT provides a promising picture, providing a patent vein lumen with high procedural success and achieving convincing early symptomatic improvement in severely symptomatic patients with impaired quality of life. In this early case series, the feasibility of the AngioJet device in elderly cases appears to be a significant problem. Therefore, patient selection is essential.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Yiğit G, Türkmen U. A preliminary experience on the efficacy, safety, and short-term results in the treatment of acute bilateral iliofemoral deep vein thrombosis with the Angiojet rheolytic thrombectomy. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 39832731. doi:10.1016/j.jvsv.2025.102192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。